Health

Diet Drug May Cause Long-Term Health Problems, FDA Says

li-qnexa-rtr2gfqh2.jpg
Qnexa may lead to heart problems and birth defects in pregnant women

U.S. health officials say they still have safety concerns about experimental diet pill Qnexa, from drugmaker Vivus Inc., as the company prepares to make a second attempt to convince experts of the drug's safety next week.

Vivus, based in Mountain View, Calif., is one of three small drugmakers racing to bring the first new prescription weight loss drug to market in more than a decade. In the past two years the Food and Drug Administration has rejected pills from all three: Arena Pharmaceuticals Inc., Orexigen Therapeutics Inc. and Vivus.

All three companies are in the process of resubmitting their products.

Qnexa is not authorized for sale in Canada, Health Canada says.

The FDA had rejected the diet pill Qnexa in October 2010. Vivus has resubmitted the drug with additional follow-up information, hoping for a more favorable ruling.

But in documents posted online Friday, the FDA reiterated concerns about two safety issues that plagued the pill the time first around: Potential heart problems and birth defects in women who become pregnant while taking the drug.

Final decision on Qnexa in April
On Wednesday the FDA will ask experts at a public meeting to weigh in on those issues, specifically risks of cleft lip defects associated with one of the ingredients in Qnexa. The experts will also discuss increased blood pressure and higher heart rates reported for patients taking the drug.

The panel of doctors will take a final vote on whether the drug appears safe and effective. The group's recommendation is not binding, and the FDA is expected to make its final decision in April.

With U.S. obesity rates nearing 35 percent among adults, doctors and public health officials say new weight-loss therapies are desperately needed. And even a modestly effective drug could have blockbuster potential. But none of the three medicines before the FDA represents a breakthrough in research.

Qnexa is a combination of two older drugs. The amphetamine phentermine, which is approved for short-term weight loss, and topiramate, an anticonvulsant drug sold by Johnson & Johnson as Topamax. Phentermine helps suppress appetite, while topiramate is supposed to make patients feel more satiated.

High weight loss reported in company studies
Many analysts had picked Qnexa as the most promising contender of the new potential diet pills because of the high level of weight loss reported in company studies. On average, patients lost more than 10 per cent of their total body mass.

But at Qnexa's first FDA panel in 2010, experts assembled by the food and drug regulator voted 10-6 to not recommend the drug's approval. Panelists said the drug was associated with a number of dangerous side effects, including suicidal thoughts, heart palpitations, memory lapses and birth defects.

On Wednesday, Vivus will offer to conduct a follow-up study to monitor patients for any heart problems, if Qnexa is approved. Experts will consider whether the company should be required to conduct that study before FDA gives approval. The company will also offer a plan to make sure women who are likely to become pregnant do not use the drug. One of the two ingredients in Qnexa, topirimate, is known to more than double the risk of birth defects.

Qnexa's other ingredient, phentermine, was one half of the dangerous fen-phen combination, a weight loss treatment pushed by doctors that was never approved by the FDA. The regimen was linked to heart-valve damage and lung problems in the late 1990s, and the FDA forced drugmaker Wyeth to withdraw two versions of its drug fenfluramine.

Currently there is just one prescription drug on the market for long-term weight loss: Roche's Xenical, which is not widely used because of modest weight loss results.

SOURCE: The Associated Press
blog comments powered by Disqus

AP WORLD
AP NATIONAL
AP WASHINGTON
AP BUSINESS
AP ENTERTAINMENT
AP ON THE HOUR
AP HEADLINES
AP BREAKING
AP/REUTERS PHOTO WIRE
AP AUDIO
 
AFP NEWS WRAP
REUTERS WORLD NEWS HIGHLIGHTS
REUTERS DIGEST
GOOGLE NEWS
ANANOVA
BLOOMBERG
DOW JONES
INDO-ASIAN NEWS SERVICE
INTERFAX
KYODO
MCCLATCHY [DC]
PRESS ASSOCIATION
PR NEWSWIRE
XINHUA
WORLD FRONT PAGES
POLITICO
REAL CLEAR POLITICS
SAN FRAN CHRON
SKY NEWS
SYDNEY MORNING HERALD
TIME MAG

CNN
CNN POLITICAL TICKER
DALLAS MORNING NEWS
EDITOR & PUBLISHER
FINANCIAL TIMES
FORBES
FORT WORTH STAR-TELEGRAM
FOX NEWS
FOX NEWS NATION
IAFRICA
INTERNATIONAL HERALD TRIB
JERUSALEM POST
JEWISH WORLD REVIEW
LA TIMES
LA DAILY NEWS
MEDIA WEEK
MSNBC
NY POST
NY TIMES
NY DAILY NEWS
NEW YORKER
NEWSBUSTERS
NEWSWEEK
NEWSMAX
CHRISTIAN POST
ONE NEWS NOW
CROSSWALK
CHRISTIANITY TODAY
US NEWS AND WORLD REPORT

CBN NEWS

CHARISMA NEWS

WORLD MAGAZINE

BLACK CHRISTIAN NEWS